Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

GILD jumps 27.2% in six months as FDA nod for twice-yearly HIV drug Yeztugo boosts its HIV franchise and growth outlook.

The Food and Drug Administration approved the preventative use of lenacapavir, made by Gilead Sciences, on Wednesday. Experts say lenacapavir is easier to administer, and each dose lasts longer ...

Prevention of HIV has become even easier with the FDA approval of lenacapavir (Yeztugo; Gilead Sciences), a twice-yearly long-acting injectable treatment that can prevent HIV in those who receive ...

FOSTER CITY, Calif., June 18, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Yeztugo® (lenacapavir)—the company’s ...

If it was hype, it was well-founded hype. In late-stage clinical trials, lenacapavir had a near-perfect record of suppressing HIV infection. Having already approved it as a treatment to reduce viral ...

The price of lenacapavir will be a big factor in how widely it is used globally. In the US, it’s currently priced at around US$28,000 per year (£22,000), but the cost of medicines often differs in ...

Lenacapavir, the first FDA-approved, twice-yearly injectable PrEP for HIV prevention, shows 96% efficacy and offers ...

Lenacapavir is a major step forward in HIV prevention. With just two injections a year, it is a simple and highly effective option for people who need protection but find daily pills difficult.

Lenacapavir could also solve major issues limiting the impact of daily PrEP pills. In real world studies, efficacy drops to as low as 60 per cent because people forget to take a tablet, or are ...

FOSTER CITY, Calif., June 18, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Yeztugo® (lenacapavir)—the company’s injectable ...

Gilead officials lauded the FDA's approval of lenacapavir, which has been studied and developed over nearly two decades. "We now have a very real opportunity to end the HIV epidemic," said Daniel ...